The U.S. Food and Drug Administration (FDA) has officially approved VIZZ, a new prescription eye drop designed to help adults who experience presbyopia, a common age-related condition that makes it difficult to see things up close.

VIZZ works by temporarily reducing the size of the pupil, a process that improves focus for near objects without significantly affecting distance vision. This creates what experts refer to as a “pinhole effect,” allowing users to read or perform close-up tasks more comfortably.

In clinical testing, many participants noticed clearer near vision within 30 minutes of using the drops, with the benefits lasting up to 10 hours. The treatment was generally well tolerated, with only mild side effects such as brief eye irritation, dimmed vision, or headaches reported in a small number of cases.

The approval of VIZZ marks an important step forward in non-surgical options for managing presbyopia. The new eye drops are expected to become available in the fall of 2025, offering adults a convenient alternative to reading glasses or other vision aids.